Human Recombinant Insulin Market Revenue 2019 | Develop Rapidly by Top Players Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Labora

According to the Addressing the Challenge and Constraints of Insulin Sources and Supply (ACCISS): 2016 report, global insulin market is largely dominated by three pharmaceutical companies: Novo Nordisk A/S, Sanofi S.A. and Eli Lilly and Company. Furthermore, Southeast Asia and Latin America accounts with higher number of smaller human recombinant insulin manufactures, than other regions.

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1797

Key manufacturers are engaged in launching novel human insulin portfolio and gaining regulatory approval for their insulin product portfolio. For instance, in August 2014, Eli Lilly and Company launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes patients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell a generic recombinant human insulin in America.

Biocon expects the product to launch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: a fast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval and indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps people living with diabetes manage blood sugar levels at mealtime.

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately.

Download PDF Report Sample @ https://www.coherentmarketinsights.com/insight/request-pdf/1797

Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.